Purpose

The primary objective of this study is to evaluate the toxicity profile of GRID therapy using dose levels of 10Gy, 15 Gy and 20Gy in pediatric osteosarcoma of the extremity.

Conditions

Eligibility

Eligible Ages
Between 5 Years and 21 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • History of cytological or histological documentation of non-metastatic extremity osteosarcoma.
  • 5-21 years of age.
  • Subject is eligible for routine chemotherapy and routine surgery for the treatment of non-metastatic extremity osteosarcoma
  • Informed consent is obtained

Exclusion Criteria

  • Females with a positive urine pregnancy test.
  • Unable to comply with study procedures

Study Design

Phase
N/A
Study Type
Interventional
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
GRID Radiotherapy
Patients will be treated with GRID Radiotherapy
  • Radiation: GRID radiotherapy
    Patients will be treated with GRID radiotherapy

Recruiting Locations

University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205
Contact:
Jose Penagaricano, MD
501-686-7284
PenagaricanoJoseA@uams.edu

More Details

NCT ID
NCT03139318
Status
Recruiting
Sponsor
University of Arkansas

Study Contact

Sandy Annis, BA
5016868274
amannis@uams.edu

Detailed Description

Subjects will receive GRID radiotherapy. GRID radiation therapy is considered a standard radiation therapy method however is not typically used in pediatric osteosarcoma patients. This protocol will evaluate whether or not the use of this therapy will provide benefit to this patient population.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.